[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Mirum Pharmaceuticals Inc (MIRM)

Mirum Pharmaceuticals Inc (MIRM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,460,936
  • Shares Outstanding, K 60,981
  • Annual Sales, $ 521,310 K
  • Annual Income, $ -23,360 K
  • EBIT $ -796 M
  • EBITDA $ -770 M
  • 60-Month Beta 0.48
  • Price/Sales 13.17
  • Price/Cash Flow 2,208.55
  • Price/Book 28.31

Options Overview Details

View History
  • Implied Volatility 51.81% (+1.71%)
  • Historical Volatility 49.62%
  • IV Percentile 77%
  • IV Rank 29.30%
  • IV High 99.96% on 04/10/26
  • IV Low 31.86% on 08/21/25
  • Expected Move (DTE 19) 0.00 (0.00%)
  • Put/Call Vol Ratio 1.71
  • Today's Volume 38
  • Volume Avg (30-Day) 55
  • Put/Call OI Ratio 0.64
  • Today's Open Interest 2,160
  • Open Int (30-Day) 2,082
  • Expected Range 105.95 to 105.95

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.77
  • Number of Estimates 5
  • High Estimate $-0.41
  • Low Estimate $-1.47
  • Prior Year $-0.12
  • Growth Rate Est. (year over year) -541.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
105.70 +0.24%
on 07/31/26
130.00 -18.50%
on 07/09/26
-11.12 (-9.50%)
since 06/30/26
3-Month
88.34 +19.94%
on 05/04/26
130.00 -18.50%
on 07/09/26
+8.64 (+8.88%)
since 04/30/26
52-Week
50.25 +110.85%
on 08/06/25
130.00 -18.50%
on 07/09/26
+54.83 (+107.26%)
since 07/30/25

Most Recent Stories

More News
Mirum Pharmaceuticals to Announce Second Quarter 2026 Financial Results and Host Conference Call on August 5, 2026

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that it will report second quarter 2026 financial results on August 5, 2026. Mirum will also host a conference...

MIRM : 105.95 (-5.90%)
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that on July 10, 2026, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting...

MIRM : 105.95 (-5.90%)
Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva

- Cohort 1 results presented at ENDO 2026 demonstrate meaningful reductions in total heterotopic ossification (HO) lesion volume, new HO lesions and flare activity in adolescents and adults with...

MIRM : 105.95 (-5.90%)
INCY : 119.52 (-2.82%)
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that on June 10, 2026, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting...

MIRM : 105.95 (-5.90%)
Mirum Pharmaceuticals and Incyte Announce Pivotal Late-Breaking Results for Zilurgisertib in Fibrodysplasia Ossificans Progressiva Accepted for Presentation at ENDO 2026

- Late-breaking rapid-fire presentation to include results from Cohort 1 of the placebo-controlled PROGRESS study evaluating zilurgisertib in fibrodysplasia ossificans progressiva (FOP)

MIRM : 105.95 (-5.90%)
INCY : 119.52 (-2.82%)
Mirum Pharmaceuticals Announces New Data from Rare Liver Disease Programs Presented at the EASL International Liver Congress 2026

- Late-breaking VISTAS results demonstrate rapid, sustained, and clinically meaningful reductions in pruritus with volixibat in primary sclerosing cholangitis (PSC) -...

MIRM : 105.95 (-5.90%)
Mirum Pharmaceuticals Enters Catalyst-Rich Stretch as LIVMARLI Sales and Pipeline Advance

Mirum Pharmaceuticals (NASDAQ:MIRM) executives said the rare disease company is entering a catalyst-heavy period, with recent positive clinical updates, ongoing commercial momentum for LIVMARLI and additional...

MIRM : 105.95 (-5.90%)
Mirum Pharmaceuticals to Present Data Showcasing Leadership in Rare Liver Diseases at the EASL International Liver Congress 2026

- Late-breaking VISTAS results demonstrate rapid, sustained, and clinically meaningful reductions in pruritus with volixibat in primary sclerosing cholangitis (PSC) -...

MIRM : 105.95 (-5.90%)
Mirum Pharma: A Rare Disease Growth Story to Watch

Mirum stock pulled back after earnings despite strong growth. Here’s why investors still see upside in the rare disease biotech company

MIRM : 105.95 (-5.90%)
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that on May 11, 2026, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting...

MIRM : 105.95 (-5.90%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Mirum Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. The company's product candidate consists of maralixibat, an investigational oral drug in development...

See More

Key Turning Points

3rd Resistance Point 118.80
2nd Resistance Point 116.13
1st Resistance Point 111.04
Last Price 105.95
1st Support Level 103.28
2nd Support Level 100.61
3rd Support Level 95.52

See More

52-Week High 130.00
Last Price 105.95
Fibonacci 61.8% 99.54
Fibonacci 50% 90.13
Fibonacci 38.2% 80.71
52-Week Low 50.25

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.